Researchers have created a new vaccine for the treatment of late-stage metastatic melanoma, an aggressive skin cancer that can resist conventional treatments because it exists in an ecosystem that suppresses the body’s immune response.
Of Interest
Beating the clock: Melanoma starts evading treatment within hours — here’s how to stop it
Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
The Promise of OBX-115, a Novel TIL Therapy, in Melanoma
Cancer treatment vaccines have been in development since 2010, when the first was approved for prostate cancer, followed by another in 2015 for melanoma. While many therapeutic (rather than preventive) cancer vaccines have been researched since then, none have received approval. A major challenge in their development is identifying tumor antigens that are distinct enough from normal cells to trigger a strong immune response.
New enzyme discovery could boost cancer immunotherapy
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.